Need for more TB vaccine field sites

Area of Science:

• Global Health
• Vaccinology
• Infectious Diseases

Background:

• The global tuberculosis (TB) epidemic is exacerbated by the HIV pandemic and the rise of drug-resistant Mycobacterium tuberculosis strains.
• Current TB vaccine development is hampered by the lack of known immunological correlates of protection and imperfect preclinical models.

Purpose of the Study:

• To highlight the urgent need for an improved TB vaccine.
• To identify key challenges in TB vaccine development, particularly the inadequacy of field site capacity for large-scale efficacy trials.

Main Methods:

• The study reviews the scientific and logistical challenges in developing new TB vaccines.
• It specifically addresses the limitations in conducting Phase IIb/III efficacy trials due to low disease incidence and insufficient infrastructure in high-burden countries.

Main Results:

• The development of new TB vaccines is time-consuming and costly.
• There is a critical shortage of suitable field sites in high-burden TB countries to conduct the large-scale Phase IIb/III efficacy trials required for licensure.

Conclusions:

• Significant investment is needed to expand clinical trial capacity in high-burden TB regions.
• This expansion is essential to accelerate the development and availability of urgently needed new TB vaccines.